Rein Therapeutics, Inc. - RNTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Value Master Fund, LP | 3.5% | 926,441 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Value-Oriented Special Situations Fund, LP | 1.9% | 500,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Advisors GP, LLC | 5.4% | 1,426,441 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Capital, LP | 17.0% | 4,468,969 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Cocke Travis W. | 17.0% | 4,468,969 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.